Rhythm Pharmaceuticals Inc (RYTM) — Cash Flow-to-Debt Ratio
Rhythm Pharmaceuticals Inc (RYTM) has a Cash Flow-to-Debt Ratio of -0.07x as of December 2025, meaning its operating cash flow of $-25.39 Million could theoretically repay 0% of its total liabilities ($342.12 Million) in one year. See RYTM current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rhythm Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Rhythm Pharmaceuticals Inc across 14 annual periods. Also explore Rhythm Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Rhythm Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Rhythm Pharmaceuticals Inc. For market capitalisation and broader financial context, see Rhythm Pharmaceuticals Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.34x | $-115.67 Million | $342.12 Million | ▲ +32.4% |
| 2024 | -0.50x | $-113.88 Million | $227.72 Million | ▲ +40.1% |
| 2023 | -0.84x | $-136.16 Million | $162.99 Million | ▲ +43.1% |
| 2022 | -1.47x | $-173.43 Million | $118.22 Million | ▲ +54.4% |
| 2021 | -3.22x | $-146.00 Million | $45.37 Million | ▲ +45.8% |
| 2020 | -5.94x | $-121.98 Million | $20.55 Million | ▼ -33.0% |
| 2019 | -4.46x | $-122.75 Million | $27.50 Million | ▼ -0.4% |
| 2018 | -4.45x | $-62.06 Million | $13.95 Million | ▼ -4.9% |
| 2017 | -4.24x | $-29.46 Million | $6.95 Million | ▲ +7.9% |
| 2016 | -4.61x | $-23.22 Million | $5.04 Million | ▼ -248.1% |
| 2015 | -1.32x | $-6.98 Million | $5.27 Million | ▲ +90.3% |
| 2014 | -13.60x | $-7.51 Million | $552.00K | ▼ -5271.1% |
| 2013 | -0.25x | $-19.16 Million | $75.65 Million | ▲ +21.6% |
| 2012 | -0.32x | $-17.83 Million | $55.21 Million | — |